| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d202e9e866984fe229f6facc38f1d740 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 |
| filingDate |
2002-06-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2003-01-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f06b1e4d84394b4430670217e37ec180
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3cddc09c7de0257cfe26bfefab1ffc50 |
| publicationDate |
2003-01-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-6509347-B2 |
| titleOfInvention |
Crystalline forms of an integrin receptor antagonist |
| abstract |
The present invention relates to novel crystalline forms of the integrin αvβ3 antagonist 3-{2-oxo-3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]imidazolidin-1-yl}-3(S)-(6-methoxy-pyridin-3-yl)-propionic acid. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004053968-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004110298-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004131504-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7122376-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7049146-B2 |
| priorityDate |
2001-06-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |